MedTrace Logo

Cytokine Adsorption in Severe, Refractory Septic Shock

NCT04910893 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-06-10

No results posted yet for this study

Summary

Septic shock and the underlying dysregulated inflammatory host-response remain a major contributor to mortality in critically ill patients. Cytokine adsorption represents an attractive approach to the treatment of septic shock. Nevertheless, its effect on circulating cytokine levels, as well as on the course of disease remains largely unassessed.

Conditions

  • Septic Shock
  • Cytokine Storm

Interventions

DEVICE

Cytokine Adsorption

Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.

OTHER

Standard of Care

Standard intensive care of patients suffering septic shock

Sponsors & Collaborators

  • CytoSorbents Europe GmbH

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Marco Maggiorini, MD · Medizinische Intensivstation D-HOER 27, UniversitatsSpital Zürich

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-27
Primary Completion
2018-08-24
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910893 on ClinicalTrials.gov